Sugi Predict

Sugi Predict / Targets / NCOA2

NCOA2

Nuclear receptor coactivator 2 (NCoA-2) (Clas · Q15596 · NCOA2 on Sugi Atlas →

36,962 patent compounds predicted against NCOA2, 24,001 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL204872 SCHEMBL204872 0.47 4/20
Iodide Iodide (SCHEMBL124471) 1.00 3/20
Iodide Iodide (SCHEMBL124472) 1.00 3/20
Iodide Iodide (SCHEMBL145145) 0.60 3/20
Iodide Iodide (SCHEMBL145146) 0.60 3/20
SCHEMBL206078 SCHEMBL206078 0.52 3/20
SCHEMBL677257 SCHEMBL677257 0.42 3/20
Pyridaben Pyridaben (SCHEMBL27429) 0.40 3/20
Methylene Blue Cation Methylene Blue Cation (SCHEMBL127316) 1.00 2/20
SCHEMBL140322 SCHEMBL140322 0.84 2/20
Iodide Iodide (SCHEMBL592814) 0.70 2/20
Iodide Iodide (SCHEMBL592815) 0.70 2/20
SCHEMBL343918 SCHEMBL343918 0.69 2/20
SCHEMBL129194 SCHEMBL129194 0.66 2/20
SCHEMBL25640 SCHEMBL25640 0.65 2/20
SCHEMBL608332 SCHEMBL608332 0.64 2/20
SCHEMBL244059 SCHEMBL244059 0.63 2/20
Perchlorate Perchlorate (SCHEMBL502589) 0.62 2/20
SCHEMBL278755 SCHEMBL278755 0.61 2/20
SCHEMBL395111 SCHEMBL395111 0.60 2/20

Clinical trials — most relevant to NCOA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Chronic Effects of Estrogen in Microcirculation PHASE4COMPLETED
Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword? PHASE4UNKNOWN
Fulvestrant in Metastatic Breast Cancer PHASE4UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer PHASE1/PHASE2RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. PHASE2UNKNOWN
A Prevention Trial in Subjects at High Risk for Breast Cancer PHASE2COMPLETED
18F-fluciclovine PET in Metastatic Castration Resistant Prostate Cancer Treated With Life Prolonging Therapies PHASE2COMPLETED
T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer PHASE2RECRUITING
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer PHASE2UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer PHASE2COMPLETED
Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women nanCOMPLETED
Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer nanACTIVE_NOT_RECRUITING
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer nanUNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome nanCOMPLETED
Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations in Chronic Hepatitis B. nanUNKNOWN
Precision High-Intensity Training Through Epigenetics (PHITE) nanCOMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects nanUNKNOWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT nanCOMPLETED
Molecular Pathways Related to Short-term Fasting Response nanCOMPLETED
The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer nanCOMPLETED
The NaBu Effect on Menstruation in Women nanRECRUITING
Epigenomic and Metabolomic Signatures of APOA2 Gene by Saturated Fat Interaction nanCOMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a NCOA2 binder may also engage these)

ProteinNameSimilarity
Q9WUI9 — 1.000 Q9WUI9 →
B5DE09 — 0.997 B5DE09 →
Q61026 — 0.997 Q61026 →
Q98TW1 — 0.995 Q98TW1 →
P70365 — 0.995 P70365 →
Q4PJW2 — 0.993 Q4PJW2 →
Q9W705 — 0.992 Q9W705 →
O09000 — 0.992 O09000 →
NCOA1 Nuclear receptor coactivator 1 0.992 landscape →
O57539 — 0.987 O57539 →
Q25637 — 0.984 Q25637 →
NCOA3 Nuclear receptor coactivator 3 0.983 landscape →
O43439 — 0.981 O43439 →
Q9NRA8 — 0.981 Q9NRA8 →
Q03297 — 0.981 Q03297 →
Q9EPU2 — 0.981 Q9EPU2 →
A5D7F6 — 0.980 A5D7F6 →
Q2IBA2 — 0.980 Q2IBA2 →
A0M8T5 — 0.980 A0M8T5 →
Q5R8Q4 — 0.979 Q5R8Q4 →
Q09YG9 — 0.979 Q09YG9 →
Q9EST3 — 0.979 Q9EST3 →
Q09YK4 — 0.979 Q09YK4 →
Q07E15 — 0.979 Q07E15 →
Q00PJ1 — 0.979 Q00PJ1 →
Q8WZ74 — 0.979 Q8WZ74 →
Q62415 — 0.979 Q62415 →
Q7T2G1 — 0.979 Q7T2G1 →
Q66IV1 — 0.979 Q66IV1 →
B9EJA2 — 0.979 B9EJA2 →